PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
A new form of electric transport in the bike industry with the use of an affordable and simple conversion kit. Swytch have developed a kinetically rechargeable add-on for existing bikes to convert them into eBikes for a range of up to 50 miles. Funding will result in additional units being manufactured and sold at a 70% margin. The products are available online and currently via 20 independent bike dealers, with over 100 more waiting on stock.
days to go:
Expired
investment:
£349,356
NGX is a nutrition company that claims to have made the world’s first genetically personalised nutrition-shake, backed by nutritionists and scientists. The company is in the process of filing a patent for its product. It asserts that recommended food guidelines are based on population averages that are generic and not suitable for achieving optimum physical, mental fitness and health. NGX claims that its customer-specific products are trustworthy as they are made based on a DNA Nutrition Test (DNT) that is unique to a person. The company is operating in the $87 billion fitness market and aims to be a major contender. NGX has sold 30,000 NGX meals since its launch in 2020, collected data on over 5,000 genetic variations, and created proprietary gene-nutrition matching algorithms. It was a finalist in the 2019 British Business Awards (Health & Wellness) and has featured in publications like Glamour, Men's/Women's Health amongst others. The company will use the investment to support customer acquisition activities, team expansion, product supply, and brand partnerships deals.
days to go:
Expired
investment:
£294,934
Occuity seeks to develop revolutionary non-invasive screening and monitoring devices for chronic diseases like diabetes and Alzheimer's. It argues that its device safely shines a low power beam of light into the eye and then collects and analyses the return signal to accurately measure structures within the eye and detect changes associated with the onset of the aforementioned diseases. Occuity is targeting three distinct markets, namely Ophthalmology, Disease Screening and Disease Monitoring, which is worth an estimated $35 billion per year. It claims that its 'Occuity Indigo' product enables earlier detection of diabetes and provides a non-contacting, pain-free glucose monitor. Occuity was awarded over £1.5 million as part of the Innovate UK grant for the development of technology within Occuity Indigo. It has also signed a partnership with one of the UK's leading ophthalmic distributors, Birmingham Optical, to distribute its PM1 pachymeter device. It states it will use 42% of the investment towards Research and Development (R&D), 23% towards sales and marketing, 20% towards management and finance, 9% towards managing CAPEX and NRE, and 6% towards paying fees.
days to go:
Expired
investment:
£2,854,857
Oneskee is the one-piece snow brand that aims to re-ignite a forgotten product category. Oneskee asserts that it successfully navigated its way through the COVID-19 pandemic recording £500,000 in online revenue with 25% online growth in the 2020-2021 financial year. It has sold 10,000 suits across 79 countries since its launch and aims to become a contender in the snow brand industry that is growing more than £1 billion each year. The company has partnered with Olympic athletes, GB Snowsport, Folie Douce, and Snowboxx and received media recognition from the likes of BBC, Vogue, InTheSnow, The Telegraph, The Independent, and Eurosport. Oneskee is also continuing its work on its patent-protected Acclimate technology and kids collection which it intends to launch in 2021. Oneskee will use the investment to accelerate the roll-out of its successful online blueprint to all ski countries and create a dedicated resource for B2B sales.
days to go:
Expired
investment:
£215,618
Tethered Drones Systems Limited (TDS) builds and develops autonomous tethered drones for use in surveillance and communications scenarios. Its product, Tethered UAV, exhibits a flight duration of 24 hours or more with secure communication via a tether. The platform can carry a range of payloads to meet client needs. The company asserts that the product has multiple uses for broadcasters such as telecasting outdoor sporting events. The UAV's blue light services, including search and rescue, holds prominence in high-risk maintenance inspections for oil and gas platforms and wind farms – both on and offshore. The company will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£73,125
